- {{heading}}
- Ab00150-10.0 Anti-HA [FE17]
- Influenza A Virus (several subtypes)
- Human IgG1
- Purified
- In Stock
- Ab00150-1.1 Anti-HA [FE17]
- Influenza A Virus (several subtypes)
- Mouse IgG1
- Purified
- In Stock
Recombinant monoclonal antibody to HA. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the EBV transformed human B cell clone FE17.
Alternative Name(s) of Target: hemagglutinin; haemagglutinin
Immunogen: Made by immortalizing IgG-expressing B cells from individuals following vaccination with seasonal influenza vaccine, containing H1 and H3 influenza Virus subtypes.
Specificity: This antibody specifically recognizes the conformational epitope in the Ca2 region of HA (as assessed by the isolation of viral escape mutants all carrying a single S to N point mutation at position 145, according to H3 numbering) in which amino acid sequences are conserved in H1N1 and H5N1 subtypes of Influenza A Virus. This antibody uses the VH4-39*01, D3-9*01, JH4*02, VL1-44*01 and JL3*02 This antibody does not cross react with HA in H2N2, H3N3, H6N1, H7N3 and H9N2 subtypes of Influenza A virus. This antibody has haemagglutination-inhibition activity.
Antibody first published in:
Corti, D. et al Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 120, 1663–1673 (2010). PMID:20389023
Note on publication:
Describes the isolation and analysis of a panel of human antibodies from vaccinated individuals and its evaluation using Virus neutralization assays.
ELISA using FE17 (Ab00150) and Influenza A HA [A/Hong Kong/483/97 (H5N1)]. Binding curves of the mouse IgG chimeric version of the Anti-HA antibody FE17 (Ab00150-1.1; red line) and isotype control (Ab00102-1.1, anti-fluorescein; orange line) to an ELISA plate coated with Influenza A HA [A/Hong Kong/483/97 (H5N1)] at a concentration of 2.5 ug/ml. A 3-fold serial dilution from 3000 to 0.0169 ng/ml was performed using Ab00150 antibody. For signal detection, a 1:4000 dilution of a HRP-conjugated anti-mouse IgG antibody was used.